- Patent Title: Substituted bicyclic compounds as farnesoid X receptor modulators
-
Application No.: US17544490Application Date: 2021-12-07
-
Publication No.: US11713312B2Publication Date: 2023-08-01
- Inventor: Dean A. Wacker , Susheel Jethanand Nara , Srinivas Cheruku , Kandhasamy Sarkunam , Firoz Ali Jaipuri , Soodamani Thangavel , Srinivas Jogi , Pavan Kalyan Kathi
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Gary Greenblatt
- Main IPC: C07D413/12
- IPC: C07D413/12 ; C07D271/06 ; A61P11/00

Abstract:
Disclosed are compounds of Formula (I):
or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
Public/Granted literature
- US20220135550A1 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS Public/Granted day:2022-05-05
Information query